{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T21:41:45Z","timestamp":1794606105204,"version":"4.9.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T00:00:00Z","timestamp":1779753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"This research was supported by the Intramural Research Program of Center for Biologics, Evaluation and Research (CBER), US FDA.","id":[{"id":"https:\/\/ror.org\/02nr3fr97","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T cell therapies have shown remarkable success in the treatment of hematologic cancers; however, their use is often accompanied by inflammatory toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). These toxicities, ranging from mild to life-threatening, are partly driven by bystander myeloid cell activation (BMCA) and the subsequent release of pro-inflammatory cytokines such as IL-6 and IL-1\u03b2. Although previous studies have described the individual contributions of GM-CSF, IFN-\u03b3, and TNF\u03b1 secreted by CAR-T cells, a comprehensive characterization of CAR-T-derived inflammatory factors has been lacking. In this study, we characterized the soluble factors secreted by activated CAR-T cells derived from human peripheral blood and assessed their role in BMCA. Comparative cytokine analyses across human T cell subsets, including CAR-T cells, identified multiple candidates involved in BMCA. Antibody-mediated neutralization confirmed that four factors, GM-CSF, IFN-\u03b3, TNF\u03b1, and GPIb\u03b1, play dominant roles in driving BMCA. Furthermore, siRNA-mediated knockdown of these factors in CAR-T cells significantly reduced BMCA without impairing their anti-tumor activity. These findings are consistent with prior reports on the inflammatory roles of GM-CSF, IFN-\u03b3, and TNF\u03b1 during CAR-T cell therapy and, importantly, identify GPIb\u03b1 as a previously unrecognized contributor to CAR-T-associated inflammatory toxicities. Targeting these factors through antibody blockade or genetic modification may represent a promising strategy to mitigate inflammatory toxicities and improve the safety of CAR-T cell therapies.<\/jats:p>","DOI":"10.1038\/s41434-026-00620-6","type":"journal-article","created":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T17:43:30Z","timestamp":1779817410000},"page":"616-627","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Characterization of CAR-T cell factors that contribute to myeloid cell activation"],"prefix":"10.1038","volume":"33","author":[{"given":"Supreet","family":"Khanal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Kamal","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Panthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Baer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1798-8863","authenticated-orcid":false,"given":"Nirjal","family":"Bhattarai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,26]]},"reference":[{"key":"620_CR1","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","volume":"21","author":"JN Brudno","year":"2024","unstructured":"Brudno JN, Kochenderfer JN. Current understanding and management of CAR T cell-associated toxicities. Nat Rev Clin Oncol. 2024;21:501\u201321.","journal-title":"Nat Rev Clin Oncol"},{"key":"620_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11:69.","journal-title":"Blood Cancer J"},{"key":"620_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40164-020-00171-5","volume":"9","author":"Z Hao","year":"2020","unstructured":"Hao Z, Li R, Meng L, Han Z, Hong Z. Macrophage, the potential key mediator in CAR-T related CRS. Exp Hematol Oncol. 2020;9:1\u201312.","journal-title":"Exp Hematol Oncol"},{"key":"620_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.693016","volume":"12","author":"JW Fischer","year":"2021","unstructured":"Fischer JW, Bhattarai N. CAR-T Cell Therapy: Mechanism, Management, and Mitigation of Inflammatory Toxicities. Front Immunol. 2021;12:693016.","journal-title":"Front Immunol"},{"key":"620_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s11899-023-00687-7","volume":"18","author":"KL Chohan","year":"2023","unstructured":"Chohan KL, Siegler EL, Kenderian SS. CAR-T cell therapy: the efficacy and toxicity balance. Curr Hematologic Malignancy Rep. 2023;18:9\u201318.","journal-title":"Curr Hematologic Malignancy Rep"},{"key":"620_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1411393","volume":"15","author":"M Rossi","year":"2024","unstructured":"Rossi M, Breman E. Engineering strategies to safely drive CAR T-cells into the future. Front Immunol. 2024;15:1411393.","journal-title":"Front Immunol"},{"key":"620_CR7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1186\/s40425-019-0767-x","volume":"7","author":"H Luo","year":"2019","unstructured":"Luo H, Wang N, Huang L, Zhou X, Jin J, Li C, et al. Inflammatory signatures for quick diagnosis of life-threatening infection during the CAR T-cell therapy. J Immunother Cancer. 2019;7:271.","journal-title":"J Immunother Cancer"},{"key":"620_CR8","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1097\/CNQ.0000000000000302","volume":"43","author":"AM Rivera","year":"2020","unstructured":"Rivera AM, May S, Lei M, Qualls S, Bushey K, Rubin DB, et al. CAR T-Cell-Associated Neurotoxicity: Current Management and Emerging Treatment Strategies. Crit Care Nurs Q. 2020;43:191\u2013204.","journal-title":"Crit Care Nurs Q"},{"key":"620_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0280-y","volume":"10","author":"S Liu","year":"2020","unstructured":"Liu S, Deng B, Yin Z, Pan J, Lin Y, Ling Z, et al. Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia. Blood Cancer J. 2020;10:15.","journal-title":"Blood Cancer J"},{"key":"620_CR10","doi-asserted-by":"publisher","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","volume":"6","author":"ML Davila","year":"2014","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014;6:224ra25.","journal-title":"Sci Transl Med"},{"key":"620_CR11","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome. Oncologist. 2018;23:943\u20137.","journal-title":"Oncologist"},{"key":"620_CR12","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/1744666X.2019.1629904","volume":"15","author":"C Kotch","year":"2019","unstructured":"Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol. 2019;15:813\u201322.","journal-title":"Expert Rev Clin Immunol"},{"key":"620_CR13","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","volume":"8","author":"BD Santomasso","year":"2018","unstructured":"Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, et al. Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia. Cancer Discov. 2018;8:958\u201371.","journal-title":"Cancer Discov"},{"key":"620_CR14","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1182\/blood-2018-05-846428","volume":"132","author":"A Nellan","year":"2018","unstructured":"Nellan A, McCully CML, Cruz Garcia R, Jayaprakash N, Widemann BC, Lee DW, et al. Improved CNS exposure to tocilizumab after cerebrospinal fluid compared to intravenous administration in rhesus macaques. Blood. 2018;132:662\u20136.","journal-title":"Blood"},{"key":"620_CR15","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","volume":"24","author":"T Giavridis","year":"2018","unstructured":"Giavridis T, van der Stegen SJC, Eyquem J, Hamieh M, Piersigilli A, Sadelain M. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade. Nat Med. 2018;24:731\u20138.","journal-title":"Nat Med"},{"key":"620_CR16","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","volume":"24","author":"M Norelli","year":"2018","unstructured":"Norelli M, Camisa B, Barbiera G, Falcone L, Purevdorj A, Genua M, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat Med. 2018;24:739\u201348.","journal-title":"Nat Med"},{"key":"620_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10928-015-9450-0","volume":"43","author":"K Ogungbenro","year":"2016","unstructured":"Ogungbenro K, Hulme S, Rothwell N, Hopkins S, Tyrrell P, Galea J. Study design and population pharmacokinetic analysis of a phase II dose-ranging study of interleukin-1 receptor antagonist. J Pharmacok Pharmacodyna. 2016;43:1\u201312.","journal-title":"J Pharmacok Pharmacodyna"},{"key":"620_CR18","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12621","volume":"281","author":"CA Dinarello","year":"2018","unstructured":"Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281:8\u201327.","journal-title":"Immunol Rev"},{"key":"620_CR19","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1182\/bloodadvances.2022008256","volume":"7","author":"M Rainone","year":"2023","unstructured":"Rainone M, Ngo D, Baird JH, Budde LE, Htut M, Aldoss I, et al. Interferon-gamma blockade in CAR T-cell therapy-associated macrophage activation syndrome\/hemophagocytic lymphohistiocytosis. Blood Adv. 2023;7:533\u20136.","journal-title":"Blood Adv"},{"key":"620_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s40164-021-00209-2","volume":"10","author":"L Zhang","year":"2021","unstructured":"Zhang L, Wang S, Xu J, Zhang R, Zhu H, Wu Y, et al. Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy. Exp Hematol Oncol. 2021;10:16.","journal-title":"Exp Hematol Oncol"},{"key":"620_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38723-y","volume":"14","author":"S Manni","year":"2023","unstructured":"Manni S, Del Bufalo F, Merli P, Silvestris DA, Guercio M, Caruso S, et al. Neutralizing IFNgamma improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies. Nat Commun. 2023;14:3423.","journal-title":"Nat Commun"},{"key":"620_CR22","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","volume":"3","author":"SR Bailey","year":"2022","unstructured":"Bailey SR, Vatsa S, Larson RC, Bouffard AA, Scarfo I, Kann MC, et al. Blockade or Deletion of IFNgamma Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies. Blood Cancer Discov. 2022;3:136\u201353.","journal-title":"Blood Cancer Discov"},{"key":"620_CR23","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","volume":"133","author":"RM Sterner","year":"2019","unstructured":"Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, et al. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts. Blood. 2019;133:697\u2013709.","journal-title":"Blood"},{"key":"620_CR24","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.1074\/jbc.AC119.007558","volume":"294","author":"M Sachdeva","year":"2019","unstructured":"Sachdeva M, Duchateau P, Depil S, Poirot L, Valton J. Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators. J Biol Chem. 2019;294:5430\u20137.","journal-title":"J Biol Chem"},{"key":"620_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.623610","volume":"12","author":"Y Chen","year":"2021","unstructured":"Chen Y, Li R, Shang S, Yang X, Li L, Wang W, et al. Therapeutic Potential of TNFalpha and IL1beta Blockade for CRS\/ICANS in CAR-T Therapy via Ameliorating Endothelial Activation. Front Immunol. 2021;12:623610.","journal-title":"Front Immunol"},{"key":"620_CR26","doi-asserted-by":"crossref","unstructured":"Ataca Atilla P, McKenna MK, Tashiro H, Srinivasan M, Mo F, Watanabe N, et al. Modulating TNFalpha activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. J Immunother Cancer 2020;8:e001229.","DOI":"10.1136\/jitc-2020-001229"},{"key":"620_CR27","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","volume":"604","author":"RC Larson","year":"2022","unstructured":"Larson RC, Kann MC, Bailey SR, Haradhvala NJ, Llopis PM, Bouffard AA, et al. CAR T cell killing requires the IFNgammaR pathway in solid but not liquid tumours. Nature. 2022;604:563\u201370.","journal-title":"Nature"},{"key":"620_CR28","doi-asserted-by":"publisher","first-page":"4674","DOI":"10.4049\/jimmunol.1600769","volume":"197","author":"ML Sentman","year":"2016","unstructured":"Sentman ML, Murad JM, Cook WJ, Wu MR, Reder J, Baumeister SH, et al. Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice. J Immunol. 2016;197:4674\u201385.","journal-title":"J Immunol"},{"key":"620_CR29","doi-asserted-by":"publisher","first-page":"4643","DOI":"10.4049\/jimmunol.173.7.4643","volume":"173","author":"AD Cook","year":"2004","unstructured":"Cook AD, Braine EL, Hamilton JA. Stimulus-dependent requirement for granulocyte-macrophage colony-stimulating factor in inflammation. J Immunol. 2004;173:4643\u201351.","journal-title":"J Immunol"},{"key":"620_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-58131-2","volume":"10","author":"N Lotfi","year":"2020","unstructured":"Lotfi N, Zhang GX, Esmaeil N, Rostami A. Evaluation of the effect of GM-CSF blocking on the phenotype and function of human monocytes. Sci Rep. 2020;10:1567.","journal-title":"Sci Rep"},{"key":"620_CR31","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/CJI.0000000000000402","volume":"45","author":"G Lamture","year":"2022","unstructured":"Lamture G, Baer A, Fischer JW, Colon-Moran W, Bhattarai N. TCR-independent Activation in Presence of a Src-family Kinase Inhibitor Improves CAR-T Cell Product Attributes. J Immunother. 2022;45:139.","journal-title":"J Immunother"},{"key":"620_CR32","doi-asserted-by":"crossref","unstructured":"Khanal S, Baer A, Bhattarai N Feeder Cell-Free Production of CAR-NK Cells via Activation of PKC and Calcium Signaling Pathways. Cytotherapy 2025;27:1013\u201322.","DOI":"10.1016\/j.jcyt.2025.05.008"},{"key":"620_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1519415","volume":"15","author":"S Khanal","year":"2024","unstructured":"Khanal S, Baer A, Hossain MK, Colon-Moran W, Panthi S, Bhattarai N. Soluble factors released by peripheral blood-derived CAR-NK cells cause bystander myeloid cell activation. Front Immunol. 2024;15:1519415.","journal-title":"Front Immunol"},{"key":"620_CR34","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/jth.12144","volume":"11","author":"R Li","year":"2013","unstructured":"Li R, Emsley J. The organizing principle of the platelet glycoprotein Ib-IX-V complex. J Thromb Haemost. 2013;11:605\u201314.","journal-title":"J Thromb Haemost"},{"key":"620_CR35","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aat6023","volume":"12","author":"F Liu","year":"2019","unstructured":"Liu F, Endo Y, Romantseva T, Wu WW, Akue A, Shen R-F, et al. T cell\u2013derived soluble glycoprotein GPIb\u03b1 mediates PGE2 production in human monocytes activated with the vaccine adjuvant MDP. Sci Signal. 2019;12:eaat6023.","journal-title":"Sci Signal"},{"key":"620_CR36","doi-asserted-by":"publisher","first-page":"3358","DOI":"10.1182\/blood.V128.22.3358.3358","volume":"128","author":"K Ishii","year":"2016","unstructured":"Ishii K, Shalabi H, Yates B, Delbrook C, Mackall CL, Fry TJ, et al. Tocilizumab-refractory cytokine release syndrome (CRS) triggered by chimeric antigen receptor (CAR)-transduced T cells may have distinct cytokine profiles compared to typical CRS. Blood. 2016;128:3358.","journal-title":"Blood"},{"key":"620_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-020-00171-5","volume":"9","author":"Z Hao","year":"2020","unstructured":"Hao Z, Li R, Meng L, Han Z, Hong Z. Macrophage, the potential key mediator in CAR-T related CRS. Exp Hematol Oncol. 2020;9:15.","journal-title":"Exp Hematol Oncol"},{"key":"620_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.577027","volume":"11","author":"J Gust","year":"2020","unstructured":"Gust J, Ponce R, Liles WC, Garden GA, Turtle CJ. Cytokines in CAR T Cell-Associated Neurotoxicity. Front Immunol. 2020;11:577027.","journal-title":"Front Immunol"},{"key":"620_CR39","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21645515.2021.2016005","volume":"18","author":"H Zhang","year":"2022","unstructured":"Zhang H, Lv X, Kong Q, Tan Y. IL-6\/IFN-\u03b3 double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro. Hum Vaccines Immunotherapeut. 2022;18:1\u201314.","journal-title":"Hum Vaccines Immunotherapeut"},{"key":"620_CR40","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1158\/0008-5472.CAN-22-2155","volume":"83","author":"P Schaible","year":"2023","unstructured":"Schaible P, Bethge W, Lengerke C, Haraszti RA. RNA Therapeutics for Improving CAR T-cell Safety and Efficacy. Cancer Res. 2023;83:354\u201362.","journal-title":"Cancer Res"},{"key":"620_CR41","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1111\/exd.13678","volume":"27","author":"B Simon","year":"2018","unstructured":"Simon B, Harrer DC, Schuler-Thurner B, Schaft N, Schuler G, Dorrie J, et al. The siRNA-mediated downregulation of PD-1 alone or simultaneously with CTLA-4 shows enhanced in vitro CAR-T-cell functionality for further clinical development towards the potential use in immunotherapy of melanoma. Exp Dermatol. 2018;27:769\u201378.","journal-title":"Exp Dermatol"},{"key":"620_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.606489","volume":"11","author":"MR Walter","year":"2020","unstructured":"Walter MR. The role of structure in the biology of interferon signaling. Front Immunol. 2020;11:606489.","journal-title":"Front Immunol"},{"key":"620_CR43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1007\/s100380170126","volume":"46","author":"M Kajita","year":"2001","unstructured":"Kajita M, Iwasaki H, Ota N, Shinohara Y, Kodaira M, Nakajima T, et al. Novel single nucleotide polymorphisms of the human colony-stimulating factor 2 (CSF2) gene identified by sequencing the entire gene. J Hum Genet. 2001;46:48\u201349.","journal-title":"J Hum Genet"},{"key":"620_CR44","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/j.cyto.2012.10.016","volume":"61","author":"BZ Camurdanoglu","year":"2013","unstructured":"Camurdanoglu BZ, Esendagli G, Ozdemir E, Canpinar H, Guc D, Kansu E. The effect of granulocyte colony stimulating factor receptor gene missense single nucleotide polymorphisms on peripheral blood stem cell enrichment. Cytokine. 2013;61:572\u20137.","journal-title":"Cytokine"},{"key":"620_CR45","doi-asserted-by":"crossref","unstructured":"Ahmed B, Aliyu M, Getso MI, Bala JA, Ahmed RJ, Kabuga AI, et al. Exploring the impact of interferon-gamma single nucleotide polymorphisms on HTLV-1 infection: Unraveling genetic influences in viral pathogenesis. Critical Reviews in Oncology\/Hematology 2025: 104614.","DOI":"10.1016\/j.critrevonc.2025.104614"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00620-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00620-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00620-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T13:58:31Z","timestamp":1789653511000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-026-00620-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,26]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["620"],"URL":"https:\/\/doi.org\/10.1038\/s41434-026-00620-6","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,26]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All blood donors provided written informed consent for the use of their samples in laboratory research. This study protocol was reviewed and exempted by the FDA IRB, Research Involving Human Subjects Committee (RIHSC). All methods described in this study were performed in accordance with relevant guidelines and regulations, including applicable institutional policies and procedures of the U.S. Food and Drug Administration.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}